Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Barry C LemberskyNorman Wolmark

Abstract

The primary aim of this study was to compare the relative efficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly intravenous fluorouracil (FU) plus LV in prolonging disease-free survival (DFS) and overall survival (OS) after primary surgery for colon carcinoma. Between February 1997 and March 1999, 1,608 patients with stage II and III carcinoma of the colon were randomly assigned to receive either oral UFT+LV or intravenous FU+LV. Of the total patients, 47% had stage II colon cancer, and 53% had stage III colon cancer. Median follow-up time was 62.3 months. The estimated hazard ratio (HR) for OS of patients who received UFT+LV versus that of patients who received FU+LV was 1.014 (95% CI, 0.825 to 1.246). The estimated HR for DFS was 1.004 (95% CI, 0.847 to 1.190). Cox proportional hazards model analyses with regard to age (< 60 v > or = 60 years), stage, or number of involved nodes (none v one to three v > or = four nodes) revealed no interaction with OS or DFS. Toxicity was similar in the two groups. In the UFT+LV arm, 38.2% of patients experienced any grade 3 or 4 toxic event compared with 37.8% of patients in the FU+LV arm. Primary quality-of-life end points did not differ between the two ...Continue Reading

References

Jan 1, 1988·Cancer Chemotherapy and Pharmacology·K OtaK Kimura
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R PazdurB Bready
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N WolmarkN J Petrelli
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardSteven E Benner
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James CarmichaelChristophe Martin
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Junichi SakamotoUNKNOWN Meta-Analysis Group in Cancer
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer

❮ Previous
Next ❯

Citations

Jul 29, 2009·Cancer Chemotherapy and Pharmacology·Sotaro SadahiroToshinori Oka
May 22, 2010·Cancer Chemotherapy and Pharmacology·Tetsuya HamaguchiUNKNOWN NSAS-CC Group
Jan 17, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lee S SchwartzbergArthur C Houts
Jul 6, 2010·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Ester J M SiemerinkGeke A P Hospers
Dec 19, 2008·International Journal of Clinical Oncology·Toshiaki Watanabe
Dec 8, 2009·International Journal of Clinical Oncology·Tomohisa FuruhataKazuaki Sasaki
May 16, 2012·International Journal of Clinical Oncology·Masaichi OgawaKatsuhiko Yanaga
Oct 14, 2011·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Been-Ren LinJin-Tung Liang
Nov 10, 2007·Current Gastroenterology Reports·Olivia Aranha, Al B Benson
Aug 8, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Cristina GrávalosAlfredo Carrato
Mar 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Paula Manchon WalshUNKNOWN Colorectal Cancer OncoGuia Group
Oct 27, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Cristina Grávalos CastroUNKNOWN SEOM (spanish Society for Medical Oncology)
Sep 13, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J MaurelUNKNOWN SEOM
Oct 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PapamichaelUNKNOWN SIOG
Oct 16, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W KoizumiY Okada
Jul 22, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A TsunodaM Kusano
Sep 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollA Cervantes
Sep 13, 2005·Japanese Journal of Clinical Oncology·Junichi SakamotoMasayuki Yasutomi
Jan 21, 2010·Japanese Journal of Clinical Oncology·Akira TsunodaYuko Tsunoda
Sep 10, 2013·Japanese Journal of Clinical Oncology·Teruhiro Utsugi
Nov 2, 2006·Journal of the National Cancer Institute·Peter GibbsIan Faragher
Jun 29, 2007·Journal of the National Cancer Institute·Cornelis J A PuntJean-Yves Douillard
Oct 15, 2011·Journal of the National Cancer Institute·Greg YothersUNKNOWN ACCENT Collaborative Group
Jul 11, 2007·The Cancer Journal·Ki Young Chung, Leonard B Saltz
Jun 9, 2010·The Cancer Journal·Benoît RousseauUNKNOWN GERCOR (French Oncology Research Group)
Jan 7, 2010·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·Q BinF Gao
May 11, 1991·BMJ : British Medical Journal·M Slevin, R Gray
Jun 1, 1992·Postgraduate Medical Journal·I Taylor
Feb 9, 2013·Oncology·Doğan UncuUNKNOWN Anatolian Society of Medical Oncology
Jul 27, 2011·Therapeutic Advances in Medical Oncology·Diogo Assed BastosPaulo M Hoff
Aug 19, 2007·BMC Genomics·Kim M Clark-LangoneMaureen T Cronin
May 6, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carmen J AllegraNorman Wolmark
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Beth A ZamboniSamuel J Wang
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J O'ConnellNorman Wolmark
Nov 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroko KunitakeClifford Y Ko
Sep 12, 2012·Annals of Surgical Oncology·Keisuke UeharaMasato Nagino

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J Philip KueblerNorman Wolmark
The New England Journal of Medicine
Chris TwelvesWerner Scheithauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jean-Yves DouillardSteven E Benner
© 2022 Meta ULC. All rights reserved